Inhibitors against cyclin-dependent kinase 4/6 (CDK4/6) are an important new class of agents with substantial antitumor activity in patients with advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) breast cancer [12–16]. This evidence concerns the gene CDK4 and breast cancer.